CD4 and influenza: By joining multiple types of Fabs that bind to different epitopes (e.g., the broadly neutralizing CD4-binding 3BNC117 with a V1V2-binding PG16), multiFabs may enhance the potency of neutralization as well as help combat HIV-1 heterogeneity as has been seen in combination influenza antibodies (Laursen et al., 2018) and HIV-1 mosaic vaccines (Bricault et al., 2019).